Therapeutic approaches to organ fibrosis - PubMed (original) (raw)
Review
Therapeutic approaches to organ fibrosis
T J Franklin. Int J Biochem Cell Biol. 1997 Jan.
Abstract
Scarring of superficial tissues and chronic fibroses of major organs present major medical problems ranging from disfigurement to progressive disability and death. Growing understanding of the cellular and molecular events, which are common to these intractable disorders, now provides a favourable basis for the development of effective drug therapies. Much attention is focussed on the roles of the many cytokines and growth factors, which contribute to the fibrogenic process. The transforming growth factor (TGF)-beta 1 and 2 isoforms are among the most significant of these and approaches to control their activity include blocking the activation of latent TGF-beta, preventing the ligand-receptor interactions and the inhibition of down-stream signal transduction. Concerns regarding possible risks of the long-term suppression of TGF-beta function point to connective tissue growth factor (CTGF) as a possible alternative target. CTGF is induced by and appears to mediate at least some of the fibrogenic actions of TGF-beta, although not its important antimitogenic activity on epithelial cells. The fibrogenic effects of endothelins and angiotensin II have aroused considerable interest in the anti-fibrotic potential of antihypertensive agents designed primarily to limit the vasoconstrictive activities of these peptides. Polypeptides including interferons alpha and gamma, relaxin, TGF-beta 3 and hepatocyte growth factor, all show an ability to limit fibrogenesis in either clinical or experimental situations. Finally, inhibitors of the enzymes required for the post-translational processing of collagens, including prolyl 4-hydroxylase, C-proteinase and lysyl oxidase provide a more direct means of reducing the deposition of fibrillar collagens into the extracellular matrix although the potentially adverse effects of sustained manipulation of collagen metabolism remain to be investigated.
Similar articles
- Connective tissue growth factor causes persistent proalpha2(I) collagen gene expression induced by transforming growth factor-beta in a mouse fibrosis model.
Chujo S, Shirasaki F, Kawara S, Inagaki Y, Kinbara T, Inaoki M, Takigawa M, Takehara K. Chujo S, et al. J Cell Physiol. 2005 May;203(2):447-56. doi: 10.1002/jcp.20251. J Cell Physiol. 2005. PMID: 15605379 - Human Fibrotic Diseases: Current Challenges in Fibrosis Research.
Rosenbloom J, Macarak E, Piera-Velazquez S, Jimenez SA. Rosenbloom J, et al. Methods Mol Biol. 2017;1627:1-23. doi: 10.1007/978-1-4939-7113-8_1. Methods Mol Biol. 2017. PMID: 28836191 Review. - How can transforming growth factor beta be targeted usefully to combat liver fibrosis?
Shek FW, Benyon RC. Shek FW, et al. Eur J Gastroenterol Hepatol. 2004 Feb;16(2):123-6. doi: 10.1097/00042737-200402000-00001. Eur J Gastroenterol Hepatol. 2004. PMID: 15075983 - Anti-TGF-beta strategies for the treatment of chronic liver disease.
Breitkopf K, Haas S, Wiercinska E, Singer MV, Dooley S. Breitkopf K, et al. Alcohol Clin Exp Res. 2005 Nov;29(11 Suppl):121S-131S. doi: 10.1097/01.alc.0000189284.98684.22. Alcohol Clin Exp Res. 2005. PMID: 16344596 Review. - Modern pathogenetic concepts of liver fibrosis suggest stellate cells and TGF-beta as major players and therapeutic targets.
Gressner AM, Weiskirchen R. Gressner AM, et al. J Cell Mol Med. 2006 Jan-Mar;10(1):76-99. doi: 10.1111/j.1582-4934.2006.tb00292.x. J Cell Mol Med. 2006. PMID: 16563223 Free PMC article. Review.
Cited by
- The Molecular Mechanisms and Function of miR-15a/16 Dysregulation in Fibrotic Diseases.
Wen D, Zhang H, Zhou Y, Wang J. Wen D, et al. Int J Mol Sci. 2022 Dec 16;23(24):16041. doi: 10.3390/ijms232416041. Int J Mol Sci. 2022. PMID: 36555676 Free PMC article. Review. - Inhibition of prolyl 4-hydroxylase in vitro and in vivo by members of a novel series of phenanthrolinones.
Franklin TJ, Morris WP, Edwards PN, Large MS, Stephenson R. Franklin TJ, et al. Biochem J. 2001 Jan 15;353(Pt 2):333-8. doi: 10.1042/0264-6021:3530333. Biochem J. 2001. PMID: 11139398 Free PMC article. - Research progress in effects of microRNA-15a and microRNA-16 on fibrotic diseases.
Wen D, Wang J. Wen D, et al. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2023 May 28;48(5):743-749. doi: 10.11817/j.issn.1672-7347.2023.220129. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2023. PMID: 37539577 Free PMC article. Chinese, English. - Relaxin in fibrotic ligament diseases: Its regulatory role and mechanism.
Yuan S, Guo D, Liang X, Zhang L, Zhang Q, Xie D. Yuan S, et al. Front Cell Dev Biol. 2023 Apr 11;11:1131481. doi: 10.3389/fcell.2023.1131481. eCollection 2023. Front Cell Dev Biol. 2023. PMID: 37123405 Free PMC article. Review. - Maternal obesity-impaired insulin signaling in sheep and induced lipid accumulation and fibrosis in skeletal muscle of offspring.
Yan X, Huang Y, Zhao JX, Long NM, Uthlaut AB, Zhu MJ, Ford SP, Nathanielsz PW, Du M. Yan X, et al. Biol Reprod. 2011 Jul;85(1):172-8. doi: 10.1095/biolreprod.110.089649. Epub 2011 Feb 23. Biol Reprod. 2011. PMID: 21349823 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous